US5206366A
(en)
*
|
1992-08-26 |
1993-04-27 |
Pfizer Inc. |
Process for preparing aryl piperazinyl-heterocyclic compounds
|
ES2083319B1
(es)
*
|
1993-09-20 |
1997-01-16 |
Pfizer |
Monohidrato de clorhidrato de 5-(2-(4-(1,2-benzisotiazol-3-il)-1-piperazinil)-etil)-6-cloro-1,3-dihidro-2h-indol-2-ona.
|
ES2210450T3
(es)
*
|
1996-02-13 |
2004-07-01 |
Pfizer Inc. |
Profarmacos de 5-(2-(4-(1,2-benzoisotiazol-3-il)-1-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona.
|
UA57734C2
(uk)
|
1996-05-07 |
2003-07-15 |
Пфайзер Інк. |
Комплекси включення арилгетероциклічних солей
|
TW491847B
(en)
*
|
1996-05-07 |
2002-06-21 |
Pfizer |
Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
|
NZ332219A
(en)
*
|
1996-05-07 |
2005-02-25 |
Pfizer |
Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one (ziprasidone), its preparation and its use as dopamine D2 antagonist
|
IL127497A
(en)
*
|
1997-12-18 |
2002-07-25 |
Pfizer Prod Inc |
Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
|
US6150366A
(en)
*
|
1998-06-15 |
2000-11-21 |
Pfizer Inc. |
Ziprasidone formulations
|
US7030142B1
(en)
*
|
1999-04-06 |
2006-04-18 |
Sepracor Inc. |
Methods for the treatment of neuroleptic and related disorders using ziprasidone metabolites
|
WO2000072847A1
(en)
*
|
1999-05-27 |
2000-12-07 |
Pfizer Products Inc. |
Ziprasidone suspension
|
US7175855B1
(en)
*
|
1999-05-27 |
2007-02-13 |
Pfizer Inc. |
Ziprasidone suspension
|
FR2802101B1
(fr)
|
1999-12-10 |
2003-02-28 |
Aventis Pharma Sa |
Association de cymemazine et d'un neuroleptique atypique
|
US6410520B2
(en)
|
2000-02-01 |
2002-06-25 |
The Procter & Gamble Company |
Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1, 1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate
|
US6562974B2
(en)
|
2000-02-01 |
2003-05-13 |
The Procter & Gamble Company |
Process for making geminal bisphosphonates
|
US20040023951A1
(en)
*
|
2001-06-18 |
2004-02-05 |
Bymaster Franklin Porter |
Combination therapy for treatment of psychoses
|
WO2003054226A2
(en)
*
|
2001-12-10 |
2003-07-03 |
Novartis Ag |
Methods of treating psychosis and schizophrenia based on a polymorphism in the ctf gene
|
US20040048876A1
(en)
*
|
2002-02-20 |
2004-03-11 |
Pfizer Inc. |
Ziprasidone composition and synthetic controls
|
UY27668A1
(es)
|
2002-02-20 |
2003-10-31 |
Pfizer Prod Inc |
Composición de ziprasidona y controles sintéticos
|
CN1320886C
(zh)
|
2002-05-17 |
2007-06-13 |
杜克大学 |
安非他酮与抗惊厥药在制备治疗肥胖症的药物的用途
|
US20050215552A1
(en)
*
|
2002-05-17 |
2005-09-29 |
Gadde Kishore M |
Method for treating obesity
|
ES2297200T3
(es)
*
|
2002-10-24 |
2008-05-01 |
Pfizer Products Inc. |
Derivados de acilo de 5-(2-(4-(1,2 bencisotiazol-3-il)-1-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona que presentan actividad neuroleptica.
|
WO2004050655A1
(en)
*
|
2002-12-04 |
2004-06-17 |
Dr. Reddy's Laboratories Limited |
Polymorphic forms of ziprasidone and its hydrochloride
|
US7488729B2
(en)
|
2002-12-04 |
2009-02-10 |
Dr. Reddy's Laboratories Limited |
Polymorphic forms of ziprasidone and its hydrochloride salt and process for preparation thereof
|
CN1255105C
(zh)
*
|
2002-12-17 |
2006-05-10 |
上海医药工业研究院 |
齐拉西酮及其盐的水溶性包合物及其制备方法
|
AU2003245027A1
(en)
*
|
2003-04-11 |
2004-11-01 |
Hetero Drugs Limited |
Novel crystalline forms of ziprasidone hydrochloride
|
PT2316456T
(pt)
*
|
2003-04-29 |
2017-09-05 |
Orexigen Therapeutics Inc |
Composições para afetar a perda de peso compreendendo naltrexona e bupropion
|
AU2004237951A1
(en)
*
|
2003-05-16 |
2004-11-25 |
Pfizer Products Inc. |
Therapeutic combinations of atypical antipsychotics with GABA modulators, anticonvulsants or benzodiazapines
|
WO2005035531A1
(en)
*
|
2003-06-03 |
2005-04-21 |
Teva Paharmaceutical Industries Ltd. |
POLYMORPHIC FORMS OF ZIPRASIDONE HCl AND PROCESSES FOR THEIR PREPARATION
|
US20050049295A1
(en)
*
|
2003-06-12 |
2005-03-03 |
Dr. Reddy's Laboratories Limited |
Process for the preparation of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1piperazinyl) ethyl)-6-chloro-1, 3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride) and its intermediate
|
WO2005040160A2
(en)
*
|
2003-10-24 |
2005-05-06 |
Teva Pharmaceutical Industries Ltd. |
Processes for preparation of ziprasidone
|
GB0326148D0
(en)
|
2003-11-10 |
2003-12-17 |
Lilly Co Eli |
Morpholine derivatives
|
JP4864719B2
(ja)
*
|
2003-11-26 |
2012-02-01 |
ファイザー・プロダクツ・インク |
Gsk−3インヒビターとしてのアミノピラゾール誘導体
|
WO2005054235A1
(en)
*
|
2003-11-28 |
2005-06-16 |
Wockhardt Limited |
Process for the preparing ziprasidone monohydrochloride hydrate
|
CN1934108A
(zh)
*
|
2003-12-18 |
2007-03-21 |
特瓦制药工业有限公司 |
齐拉西酮碱的多晶型b2
|
EP1703898A2
(en)
*
|
2003-12-31 |
2006-09-27 |
Alpharma, Inc. |
Ziprasidone formulations
|
CA2553207A1
(en)
*
|
2004-01-13 |
2005-08-04 |
Kishore M. Gadde |
Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss
|
US7713959B2
(en)
*
|
2004-01-13 |
2010-05-11 |
Duke University |
Compositions of an anticonvulsant and mirtazapine to prevent weight gain
|
ATE451367T1
(de)
*
|
2004-02-27 |
2009-12-15 |
Ranbaxy Lab Ltd |
Verfahren zur herstellung von ziprasidon
|
WO2005100348A1
(en)
*
|
2004-04-15 |
2005-10-27 |
Lupin Limited |
Amorphous ziprasidone hydrochloride
|
WO2005102366A2
(en)
*
|
2004-04-19 |
2005-11-03 |
Philip Maxwell Satow |
Lithium combinations, and uses related thereto
|
JP2007536229A
(ja)
*
|
2004-05-03 |
2007-12-13 |
デューク・ユニバーシティー |
体重減少に作用するための組成物
|
EP1744750A2
(en)
*
|
2004-05-06 |
2007-01-24 |
Sandoz AG |
Pharmaceutical composition comprising hydrophobic drug having improved solubility
|
ITMI20040944A1
(it)
*
|
2004-05-11 |
2004-08-11 |
Dinamite Dipharma S P A In For |
Polimorfo di ziprasidone cloridrato e procedimento per la sua preparazione
|
CA2467538C
(en)
*
|
2004-05-14 |
2010-08-24 |
Apotex Pharmachem Inc. |
New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
|
US20070237828A1
(en)
*
|
2004-06-11 |
2007-10-11 |
Dr. Reddy's Laboratories Limited |
Ziprasidone Dosage Form
|
CA2471219A1
(en)
*
|
2004-06-14 |
2005-12-14 |
Apotex Pharmachem Inc. |
Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
|
TW200612905A
(en)
*
|
2004-06-16 |
2006-05-01 |
Janssen Pharmaceutica Nv |
Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
|
MY147767A
(en)
*
|
2004-06-16 |
2013-01-31 |
Janssen Pharmaceutica Nv |
Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
|
TW200616608A
(en)
*
|
2004-07-09 |
2006-06-01 |
Forest Laboratories |
Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
|
EA010977B1
(ru)
*
|
2004-08-24 |
2008-12-30 |
Янссен Фармацевтика Н.В. |
Бензоконденсированные гетероарилсульфамидные производные, полезные в качестве противоконвульсивных средств
|
US9044503B2
(en)
*
|
2004-08-27 |
2015-06-02 |
University Of Kentucky Research Foundation |
Amyloid peptide inactivating enzyme to treat alzheimer's disease peripherally
|
US7777037B2
(en)
*
|
2004-10-27 |
2010-08-17 |
Dr. Reddy's Laboratories Limited |
Ziprasidone process
|
CA2487003C
(en)
*
|
2004-11-05 |
2012-03-13 |
Apotex Pharmachem Inc. |
Process for the preparation of ziprasidone (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one)
|
US20070032511A1
(en)
*
|
2005-02-11 |
2007-02-08 |
Judith Aronhime |
Amorphous ziprasidone mesylate
|
CA2500667C
(en)
*
|
2005-03-11 |
2013-01-15 |
Apotex Pharmachem Inc. |
Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions
|
WO2006098834A2
(en)
*
|
2005-03-14 |
2006-09-21 |
Teva Pharmaceutical Industries Ltd. |
Crystalline forms of ziprasidone mesylate
|
WO2006099452A1
(en)
*
|
2005-03-14 |
2006-09-21 |
Teva Pharmaceutical Industries Ltd. |
Anhydrous ziprasidone mesylate and a process for its preparation
|
CA2605447A1
(en)
*
|
2005-04-22 |
2006-11-02 |
Wyeth |
Therapeutic combinations for the treatment or prevention of psychotic disorders
|
MX2007014613A
(es)
*
|
2005-05-20 |
2008-04-02 |
Johnson & Johnson |
Procedimiento para la preparacion de derivados de sulfamida.
|
WO2007067341A2
(en)
|
2005-11-22 |
2007-06-14 |
Orexigen Therapeutics, Inc. |
Compositions and methods for increasing insulin sensitivity
|
US20070155827A1
(en)
*
|
2005-12-19 |
2007-07-05 |
Smith-Swintosky Virginia L |
Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
|
US8497298B2
(en)
*
|
2005-12-19 |
2013-07-30 |
Janssen Pharmaceutica Nv |
Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
|
US8691867B2
(en)
*
|
2005-12-19 |
2014-04-08 |
Janssen Pharmaceutica Nv |
Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
|
US8937096B2
(en)
|
2005-12-19 |
2015-01-20 |
Janssen Pharmaceutica Nv |
Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
|
US20070155823A1
(en)
*
|
2005-12-19 |
2007-07-05 |
Smith-Swintosky Virginia L |
Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
|
US8716231B2
(en)
*
|
2005-12-19 |
2014-05-06 |
Janssen Pharmaceutica Nv |
Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
|
US20070155824A1
(en)
*
|
2005-12-19 |
2007-07-05 |
Smith-Swintosky Virginia L |
Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis
|
AR058389A1
(es)
*
|
2005-12-19 |
2008-01-30 |
Janssen Pharmaceutica Nv |
Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
|
US20070191474A1
(en)
*
|
2006-02-15 |
2007-08-16 |
Smith-Swintosky Virginia L |
Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
|
US20070191460A1
(en)
*
|
2006-02-15 |
2007-08-16 |
Smith-Swintosky Virginia L |
Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Disease Modification / Epileptogenesis
|
US20070191450A1
(en)
*
|
2006-02-15 |
2007-08-16 |
Smith-Swintosky Virginia L |
Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Mania and Bipolar Disorder
|
US20070191451A1
(en)
*
|
2006-02-15 |
2007-08-16 |
Smith-Swintosky Virginia L |
Use of benzo-heteroaryl sulfamide derivatives as neuroprotective agents
|
HU230479B1
(hu)
*
|
2006-05-02 |
2016-07-28 |
Richter Gedeon Nyrt. |
Eljárás 5-{2-[4-(1,2-benzizotiazol-3-il)-1-piperazinil]-etil}-6-klór-1,3-dihidro-2H-indol-2-on (Ziprasidon) előállítására
|
TW200812573A
(en)
*
|
2006-05-19 |
2008-03-16 |
Janssen Pharmaceutica Nv |
Co-therapy for the treatment of epilepsy and related disorders
|
US8916195B2
(en)
*
|
2006-06-05 |
2014-12-23 |
Orexigen Therapeutics, Inc. |
Sustained release formulation of naltrexone
|
ATE523602T1
(de)
*
|
2006-06-12 |
2011-09-15 |
Hadasit Med Res Service |
Mit durch antipsychotika induzierten extrapyramidalen symptomen assoziierte rgs2- genotypen
|
KR20140088619A
(ko)
*
|
2006-11-09 |
2014-07-10 |
오렉시젠 세러퓨틱스 인크. |
단위 용량 팩키지
|
ES2344440T3
(es)
|
2006-11-09 |
2010-08-26 |
Orexigen Therapeutics, Inc. |
Formulaciones farmaceuticas en capas que comprenden una capa intermedia de disolucion rapida.
|
HUP0600868A3
(en)
*
|
2006-11-24 |
2009-03-30 |
Richter Gedeon Nyrt |
5-{2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl}-6-chloro-1,3-dihydro-2h-indol-2-one hydrogen bromide polimorphs and process for their preparation
|
AU2008254957A1
(en)
*
|
2007-05-18 |
2008-11-27 |
Scidose Llc |
Ziprasidone formulations
|
WO2009032558A2
(en)
*
|
2007-08-31 |
2009-03-12 |
Dr. Reddy's Laboratories Ltd. |
Preparation of ziprasidone hydrochloride monohydrate
|
US8410268B2
(en)
*
|
2008-03-11 |
2013-04-02 |
Alkem Laboratories Limited |
Process for the preparation of ziprasidone
|
US20090247617A1
(en)
*
|
2008-03-26 |
2009-10-01 |
Abdel-Magid Ahmed F |
Process for the preparation of benzo-fused heteroaryl sulfamates
|
US20090247616A1
(en)
*
|
2008-03-26 |
2009-10-01 |
Smith-Swintosky Virginia L |
Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
|
US20110034565A1
(en)
|
2008-04-18 |
2011-02-10 |
University College Dublin, National University Of Ireland, Dublin |
Psycho-pharmaceuticals
|
US20110144145A1
(en)
*
|
2008-05-30 |
2011-06-16 |
Orexigen Therapeutics, Inc. |
Methods for treating visceral fat conditions
|
US8809385B2
(en)
|
2008-06-23 |
2014-08-19 |
Janssen Pharmaceutica Nv |
Crystalline form of (2S)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
|
US8815939B2
(en)
*
|
2008-07-22 |
2014-08-26 |
Janssen Pharmaceutica Nv |
Substituted sulfamide derivatives
|
WO2010073255A1
(en)
*
|
2008-12-23 |
2010-07-01 |
Cadila Healthcare Limited |
Process for preparing ziprasidone
|
US8252801B1
(en)
|
2009-06-03 |
2012-08-28 |
Abbott Laboratories |
Treatment of schizophrenia and related disorders
|
JP6076740B2
(ja)
|
2010-01-07 |
2017-02-08 |
アルカーメス ファーマ アイルランド リミテッド |
第四級アンモニウム塩プロドラッグ
|
CN102724878A
(zh)
|
2010-01-11 |
2012-10-10 |
奥雷西根治疗公司 |
在重度抑郁症患者中提供体重减轻疗法的方法
|
CN102234272A
(zh)
*
|
2010-04-21 |
2011-11-09 |
上海医药工业研究院 |
盐酸齐拉西酮半水合物的制备方法
|
US20130108701A1
(en)
|
2010-05-25 |
2013-05-02 |
Krishna Murthy Bhavanasi |
Solid Dosage Forms of Antipsychotics
|
PL391810A1
(pl)
|
2010-07-14 |
2012-01-16 |
Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna |
Nowe sole ziprasidonu oraz sposoby ich otrzymywania
|
WO2012020424A1
(en)
|
2010-08-12 |
2012-02-16 |
Arch Pharmalabs Limited |
A short process for the preparation of ziprasidone and intermediates thereof
|
RS65091B1
(sr)
|
2010-08-23 |
2024-02-29 |
Alkermes Pharma Ireland Ltd |
Postupci za lečenje povećanja telesne težine indukovanog antipsihoticima
|
BR112013012062B1
(pt)
|
2010-11-15 |
2020-06-02 |
Agenebio, Inc |
Composto derivado da piridazina ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e uso do composto
|
SI23610A
(sl)
|
2011-01-13 |
2012-07-31 |
Diagen@d@o@o |
Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
|
PE20150358A1
(es)
|
2012-06-06 |
2015-04-06 |
Orexigen Therapeutics Inc |
Metodos para el tratamiento del sobrepeso y de la obesidad
|
EP3610890A1
(en)
|
2012-11-14 |
2020-02-19 |
The Johns Hopkins University |
Methods and compositions for treating schizophrenia
|
JP6883988B2
(ja)
|
2013-12-20 |
2021-06-09 |
エージンバイオ, インコーポレイテッド |
ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
|
WO2016205739A1
(en)
|
2015-06-19 |
2016-12-22 |
Belew Mekonnen |
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
|
US20170323239A1
(en)
|
2016-05-06 |
2017-11-09 |
General Electric Company |
Constrained time computing control system to simulate and optimize aircraft operations with dynamic thermodynamic state and asset utilization attainment
|
US20180170941A1
(en)
|
2016-12-19 |
2018-06-21 |
Agenebio, Inc. |
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
|
BR112019012821A2
(pt)
|
2016-12-19 |
2019-11-26 |
Agenebio Inc |
derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
|
BR112020026062B1
(pt)
|
2018-06-19 |
2023-04-04 |
Agenebio, Inc |
Compostos derivados de benzodiazepina ou um sal farmaceuticamente aceitavel, isômero ou combinação dos mesmos, composição farmacêutica compreendendo os mesmos e usos dos mesmos para o tratamento de comprometimento cognitivo, câncer cerebral e psicose da doença de parkinson
|
US20240132513A1
(en)
|
2022-08-19 |
2024-04-25 |
Agenebio, Inc. |
Benzazepine derivatives, compositions, and methods for treating cognitive impairment
|